In addition to pCR, tumor staging, molecular subtype, histological characteristics, basic patient information, and treatment methods also have an impact on the prognosis of patients with HER-2-positive breast cancer (Ryu et al., 2017; Hwang et al., 2019). The gene discussed is ERBB2; the disease is breast carcinoma.